Not Signed In -
Triamcinolone Nasal Inhalation |
Nasacort; Nasacort AQ; Tri Nasal |
Clinical Trial: Triamcinolone Acetonide as an Adjunctive to VPDT in ARMD.
This study is currently recruiting patients.
Verified by Canadian Retinal Trials Group September 2005
|
Purpose
A 24 - month Study looking at the the changes in visual acuity of patients receiving PDT therapy in conjunction with intravitreal triamcinolone.
| Condition | Intervention | Phase |
|---|---|---|
| Age-Related Macular Degeneration | Drug: Triamcinolone Acetonide | Phase II Phase III |
MedlinePlus related topics: Macular Degeneration
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: Triamcinolone Acetonide as an Adjunctive Treatment to Verteporfin Therapy in Neovascular Age-Related Macular Degeneration: Randomized Placebo-Controlled Clinical Trial.
Further Study Details:
Primary Outcomes: Changes in visual acuity from baseline.
Secondary Outcomes: Change in lesion characteristics from baseline.
Expected Total Enrollment: 120
Secondary Outcomes: Change in lesion characteristics from baseline.
Expected Total Enrollment: 120
Study start: January 2004; Expected completion: December 2007
Last follow-up: January 2007; Data entry closure: April 2007
This study will evaluate the effect of Triamcinolone Acetonide in conjunction with photodynamic therapy for the treatment of sub-foveal choroidal neovascular membranes secondary to age-related macular degeneration.
Eligibility
Ages Eligible for Study: 50 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Individuals with predominantly classic, subfoveal CNV secondary to AMD.
- No previous PDT Treatment in study eye.
Exclusion Criteria:
- CNV from conditions, other than AMD.
- Other disease that could be responsible for decreased vision.
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00148551
Canada, British Columbia
Eye Care Centre, Vancouver, British Columbia, Canada; Recruiting
Dawn Hay, R.N. 604.875.4411 Ext. 62544
Melissa Witzigmann, BSc 604-875-5285
Melissa Witzigmann, BSc 604-875-5285
Study chairs or principal investigators
David A Maberley, M.D., Study Director, University of British Columbia
More Information
Study ID Numbers: 01 (C03 - 0236)
Last Updated: September 7, 2005
Record first received: September 6, 2005
ClinicalTrials.gov Identifier: NCT00148551
Health Authority: Canada: Health Canada
ClinicalTrials.gov processed this record on 2005-09-13
Last Updated: September 7, 2005
Record first received: September 6, 2005
ClinicalTrials.gov Identifier: NCT00148551
Health Authority: Canada: Health Canada
ClinicalTrials.gov processed this record on 2005-09-13
email this page
print this page
bookmark this page
feedback on this page
